Clinical Trials Directory

Trials / Conditions / B-cell Acute Lymphoblastic Leukemia (B-ALL)

B-cell Acute Lymphoblastic Leukemia (B-ALL)

14 registered clinical trials studyying B-cell Acute Lymphoblastic Leukemia (B-ALL) — 11 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Par
NCT07422337
Arkansas Children's Hospital Research Institute—
RecruitingStudy of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic
NCT07109219
AstraZenecaPhase 1 / Phase 2
RecruitingCAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
NCT07048535
St. Jude Children's Research Hospital—
RecruitingA Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refract
NCT07205315
Grit BiotechnologyEARLY_Phase 1
Not Yet RecruitingRN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
NCT07113496
The First Affiliated Hospital with Nanjing Medical UniversityPhase 1
RecruitingStudy of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
NCT06785324
University of ChicagoN/A
RecruitingNewly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06882057
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2 / Phase 3
RecruitingNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
NCT06764238
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2 / Phase 3
RecruitingJY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06514768
920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaEARLY_Phase 1
RecruitingAZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118
AstraZenecaPhase 1 / Phase 2
Active Not RecruitingStudy of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496
Novartis PharmaceuticalsPhase 1
RecruitingAutologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Pr
NCT05480449
Stephan Grupp MD PhDPhase 1 / Phase 2
WithdrawnNovel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
NCT05513612
Shanghai Pudong HospitalPhase 1
UnknownThe Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04166838
Shanghai Longyao Biotechnology Inc., Ltd.EARLY_Phase 1